Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

LA JOLLA, Calif., Nov. 16 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor. The three co-leaders of the Company's Series A financing, ARCH Venture Partners, Polaris Venture Partners and Venrock, also participated in the latest round of financing. In conjunction with the funding, Carl Weissman, managing director at OVP Venture Partners, joined the Company's board of directors.

"Fate Therapeutics has made rapid progress in advancing its pipeline of Stem Cell Modulators and in establishing the leading industrialized platform for induced pluripotent stem cell technology," said Mr. Weissman. "We are confident that the Company's management team and its scientists will continue to identify novel mechanisms to selectively intervene in adult stem cell biology for medicine, and we believe its expert knowledge, innovative approach and advanced technologies in modulating cell fate can be leveraged across a broad therapeutic spectrum of drug discovery and development opportunities."

"The leadership of OVP, the continued support of our top-tier existing investors, and the breadth of drug development and commercialization expertise of our corporate investor syndicate creates a powerful foundation for the expansion of our stem cell biology discovery engine," said Paul Grayson, president and CEO of Fate Therapeutics. "Target populations of adult stem cells must be exquisitely characterized and quantitated, and we are employing genomic, proteomic and epigenetic expression technologies to identify cell-specific biological mechanisms to modulate cell fate for diseases that currently have limited to no tre
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 The Board of Directors of BD (Becton, ... a quarterly dividend of 54.5 cents per common share payable ... 9, 2014. The indicated annual dividend rate is $2.18 per ... a leading medical technology company that partners with customers and ... evolving health needs. Our innovative solutions are focused on improving ...
(Date:7/22/2014)...   BioTE Medical , a leading provider ... pellets, today announced the addition of Dr. ... Rouzier is joining the BioTE Medical Advisory Board ... Rouzier was residency trained in Family Medicine and ... certified emergency physician still practicing at a large ...
(Date:7/22/2014)... Chicago, IL (PRWEB) July 22, 2014 ... will a clear and concise visual representation of history, ... Mr. Novak was always regaled by family history stories ... historic location as the "old country." Pictures and 8mm ... and undiscovered side of the family, and Steve ordered ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 /PRNewswire/ ... filiale di BGI, la maggiore organizzazione di genomica del ... servizio di sequenziamento dell,intero esoma umano con base la ... Complete Genomics, molto apprezzata nel settore per essere ... il 99.999% di precisione e una rilevazione altamente sensibile ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2
... Mich., Sept. 10 The primary objective of ... the delivery of,biomedical advances to the marketplace. ... at Boston University on,Friday, September 7th with noted ... Presidents of both Boston,University and Fraunhofer Gesellschaft. ...
... by prominent,Board members Robert Windom, M.D. and Steven ... with inventor Dr. Budimir Drakulic -,have this day ... approved, ambulatory 12-lead ECG cardiovascular,monitor. In private ... ten,days, the trio of cardiovascular experts and Signalife,s ...
... (Amex: PTN ) today announced it has ... melanocortin agonist drug,candidate for the treatment of male ... King Pharmaceuticals Inc. (NYSE: KG ). ... development,and marketing agreement on bremelanotide, with King exercising ...
Cached Biology Technology:'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 3Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 2Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 3
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... NY -- Stem cells offer much promise for treating ... stem cell survival is poor, limiting their effectiveness. New ... survival and optimize their therapeutic function after transplantation, as ... Access , a peer-reviewed journal from Mary Ann Liebert, ... BioResearch Open Access website . ...
(Date:7/22/2014)... hear that drinking milk helps make their bones strong or that ... the idea that if something is good for us, it must ... Journal of Consumer Research , when children hear about the benefits ... predicted that when food is presented to children as making them ... learning how to read or count, they would conclude the food ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2
... academic, government and industry researchers has completed a first draft ... important first step in accelerating the pace of research on ... that face cassava farmers around the world. Cassava is ... for more than 750 million people each day. Although it ...
... 9 Genencor, a division of Danisco, has ... American Institute of Chemical Engineers (AIChE) for its ... Robert Davis, Chair of the AIChE Awards committee, ... Marketing Director, Biomass Enzymes and Accellerase® Product Manager, ...
... A chemical culprit responsible for the rapid, mysterious death ... found by collaborating scientists at Rutgers University and the ... may hold unexpected promise in cancer research. The ... in a virus that has been attacking and killing ...
Cached Biology News:Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... A cleaning agent for removing ... countertops, and pipettors. It ... RNase contamination from microcentrifuge tubes ... ,RNase Zap (R) ...
Mol wt: average mol wt12,360.96 Da by calculation...
... a series of media originally developed at the ... for the large scale propagation of cells from ... used for the growth and maintenance of cell ... viruses in these cell lines. One of the ...
Biology Products: